Meeting
2011 ASCO Annual Meeting
Phase I study of irinotecan and temsirolimus in patients with refractory sarcomas.
Authors
S. Movva
Emory University, Atlanta, GA
S. Movva , T. Bocklage , B. Schmit , R. Quinn , B. J. Liem , C. F. Verschraegen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT00996346
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10027)
Abstract #
10027
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.
First Author: Taofeek K. Owonikoko
Poster
2012 ASCO Annual Meeting
Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study.
First Author: Rochelle Bagatell
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2023 ASCO Annual Meeting
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
First Author: Christian Frederick Meyer